These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 16892920

  • 1. Cost effectiveness of statin therapy for the primary prevention of coronary heart disease.
    Walshe V, Nash A, Barry M.
    Ir Med J; 2006 May; 99(5):144-5. PubMed ID: 16892920
    [Abstract] [Full Text] [Related]

  • 2. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY, Ko SK, Liew D.
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of raising HDL cholesterol by adding prolonged-release nicotinic acid to statin therapy in the secondary prevention setting: a French perspective.
    Roze S, Ferrières J, Bruckert E, Van Ganse E, Chapman MJ, Liens D, Renaudin C.
    Int J Clin Pract; 2007 Nov; 61(11):1805-11. PubMed ID: 17850322
    [Abstract] [Full Text] [Related]

  • 4. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
    Chan PS, Nallamothu BK, Gurm HS, Hayward RA, Vijan S.
    Circulation; 2007 May 08; 115(18):2398-409. PubMed ID: 17452609
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010.
    Fidan D, Unal B, Critchley J, Capewell S.
    QJM; 2007 May 08; 100(5):277-89. PubMed ID: 17449875
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.
    Peura P, Martikainen J, Soini E, Hallinen T, Niskanen L.
    Curr Med Res Opin; 2008 Jun 08; 24(6):1823-32. PubMed ID: 18485270
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD, Rattinger GB, Kuznik A, Koren MJ.
    Clin Ther; 2008 Jun 08; 30 Pt 2():2204-16. PubMed ID: 19281915
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cost effectiveness of statins for the secondary prevention of coronary heart disease in Ireland.
    Barry M, Heerey A.
    Ir Med J; 2002 May 08; 95(5):133-5. PubMed ID: 12092692
    [No Abstract] [Full Text] [Related]

  • 12. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.
    Greving JP, Visseren FL, de Wit GA, Algra A.
    BMJ; 2011 Mar 30; 342():d1672. PubMed ID: 21450800
    [Abstract] [Full Text] [Related]

  • 13. Cost effectiveness of statins in coronary heart disease.
    Franco OH, Peeters A, Looman CW, Bonneux L.
    J Epidemiol Community Health; 2005 Nov 30; 59(11):927-33. PubMed ID: 16234419
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan.
    Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T.
    Int J Cardiol; 2005 Sep 30; 104(2):213-23. PubMed ID: 16168816
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
    Atthobari J, Asselbergs FW, Boersma C, de Vries R, Hillege HL, van Gilst WH, Gansevoort RT, de Jong PE, de Jong-van den Berg LT, Postma MJ, PREVEND IT Study Group.
    Clin Ther; 2006 Mar 30; 28(3):432-44. PubMed ID: 16750458
    [Abstract] [Full Text] [Related]

  • 16. The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study.
    Marshall T.
    Eur J Cardiovasc Prev Rehabil; 2006 Aug 30; 13(4):523-8. PubMed ID: 16874140
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of optimizing use of statins in Australia: using outpatient data from the REACH Registry.
    Ademi Z, Reid CM, Hollingsworth B, Stoelwinder J, Steg PG, Bhatt DL, Vale M, Liew D, Reach Registry Investigators.
    Clin Ther; 2011 Oct 30; 33(10):1456-65. PubMed ID: 21982384
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pharmaco-economic aspects of lipid-lowering therapy: is it worth the price?
    Szucs TD.
    Eur Heart J; 1998 Oct 30; 19 Suppl M():M22-8. PubMed ID: 9821013
    [Abstract] [Full Text] [Related]

  • 20. The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices.
    Plans-Rubió P.
    Am J Cardiovasc Drugs; 2010 Oct 30; 10(6):369-82. PubMed ID: 21090830
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.